Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
218.82
-5.29 (-2.36%)
At close: Jun 1, 2026, 4:00 PM EDT
218.82
0.00 (0.00%)
After-hours: Jun 1, 2026, 4:15 PM EDT
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 246.60M EUR in the quarter ending March 31, 2026, with 144.27% growth. This brings the company's revenue in the last twelve months to 865.78M, up 134.82% year-over-year. In the year 2025, Ascendis Pharma had annual revenue of 720.13M with 98.03% growth.
Revenue (ttm)
865.78M EUR
Revenue Growth
+134.82%
P/S Ratio
13.70
Revenue / Employee
728,158 EUR
Employees
1,189
Market Cap
13.59B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
| Dec 31, 2018 | 10.58M | 9.05M | 591.57% |
| Dec 31, 2017 | 1.53M | -3.08M | -66.78% |
| Dec 31, 2016 | 4.61M | -3.51M | -43.26% |
| Dec 31, 2015 | 8.12M | -5.87M | -41.94% |
| Dec 31, 2014 | 13.98M | -6.43M | -31.48% |
| Dec 31, 2013 | 20.41M | 4.83M | 30.96% |
| Dec 31, 2012 | 15.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
ASND News
- 14 days ago - Ascendis Pharma initiated with a Buy at Citi - TheFly
- 17 days ago - Ascendis Pharma price target raised to $329 from $324 at Evercore ISI - TheFly
- 21 days ago - Ascendis Pharma price target raised to $345 from $342 at Barclays - TheFly
- 24 days ago - Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo - TheFly
- 25 days ago - Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15) - TheFly
- 25 days ago - Ascendis Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 25 days ago - Ascendis Pharma Earnings release: Q1 2026 - Filings
- 25 days ago - Ascendis Pharma Reports First Quarter 2026 Financial Results - GlobeNewsWire